Important to remember that when you say “the Vax” that we have 2 programs. HSV-2 (as you described), and HPV (head & neck focus in the clinical trial that is about to begin).
Wayne says he is excited by the potential of this program, and incredible results were seen in mouse models.
I certainly think there is some value in the vaccines business. (Though I would rather divest a large portion of our shares, and use the capital to ramp up sales and marketing for Regen)
Under the Radar, page-41
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
0.000(0.00%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.80 | $96.66K | 9.794K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 286 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.99 | 198 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |